Article Summary
Side-chain chemistry of iodine-based contrast media may help radiologists empirically select safer alternative agents for patients with prior hypersensitivity reactions when comprehensive allergy testing is unavailable, although formal allergy evaluation remains the gold standard.
- Group 1 contrast agents, including iohexol, iodixanol, iomeprol, and ioversol, showed the highest cross-reactivity rates, suggesting that agents from a different structural group may be preferable after a reaction to one of these agents.
- Iobitridol demonstrated low cross-reactivity, while iopamidol showed a more variable profile but may still be considered in some settings when allergy testing cannot be performed immediately.
- Updated ESUR guidelines no longer recommend routine premedication and instead emphasize switching to tolerated alternative agents based on allergologic evaluation
- Accurate documentation of the hypersensitivity reaction—including specific agent name, dose, symptoms, and therapy—is essential for guiding future imaging decisions
- Evidence is limited to observational studies and skin-test results rather than large randomized trials, so this framework supports but cannot replace comprehensive allergy evaluation
A patient develops a hypersensitivity reaction after receiving iodine-based contrast media (ICM) during a CT examination, with symptoms ranging from itching, hives, and skin rash to swelling, breathing difficulties and, in rare cases, life-threatening anaphylaxis.
Weeks later, the patient requires another contrast-enhanced CT examination. Yet the formal allergy work-up can't wait for weeks or months, especially if the examination is too urgent to delay. Which contrast agent should the radiologist use next?
The choice is between trial and error with any alternative contrast agent, or to give an alternative contrast agent based on side-chain chemistry and its cross-reactivity pattern.
A new review published in European Radiology led by Dr. Aart J. van der Molen of Leiden University Medical Center in Leiden, the Netherlands, together with Dr. Francisco Vega of Hospital Universitario de La Princesa in Madrid, Spain; and Dr. Ingrid Böhm of Inselspital, Bern University Hospital, in Bern, Switzerland, explores whether this approach can help guide the empirical selection of a safer alternative when a comprehensive allergologic evaluation is unavailable.
From premedication to contrast substitution
The review builds on the team's 2024 proposal published in the European Journal of Radiology to classify iodinated contrast agents according to their side-chain chemistry and examines whether newer evidence supports that framework in clinical practice. The question has become increasingly relevant as the management of contrast media hypersensitivity continues to evolve.
Updated guidance from the European Society of Urogenital Radiology (ESUR) Contrast Media Safety Committee no longer recommends routine corticosteroid or antihistamine premedication because evidence that it prevents moderate or severe hypersensitivity reactions remains limited.
The review follows growing evidence that in this era of nonionic low-osmolar ICM use substituting the culprit contrast agent is more effective than relying on routine premedication to prevent recurrent reactions, shifting attention toward how radiologists should choose that alternative.
Instead, the guidelines emphasize allergy evaluation after prior moderate-to-severe reactions and recommend switching to a tolerated alternative contrast agent whenever possible. In practice, however, that is often easier said than done.
"We are emailed regularly by frustrated radiologists across Europe," van der Molen told AuntMinnie Europe, pointing to limited access to allergists and long waiting times in many countries. He said that in many healthcare systems, empirically changing the contrast agent remains the most common strategy simply because specialist allergy services are not readily available.
"If there is little else for a radiologist, or in emergency situations, this evidence may help guide the selection of a safer alternative ICM."
Heat map of cross-reactivity patterns between iodine-based contrast media. Red indicates higher cross-reactivity and green indicates lower cross-reactivity based on available skin-test data.Image courtesy of Aart J. van der Molen, MD, et al., European Journal of Radiology (2026).
Cross-reactivity is a complex issue
The cross-reactivity between ICM is a complex issue, with individual reaction patterns in patients. Instead of recommending a random switch, the authors argue that choosing an alternative contrast agent from a different structural group may help to reduce the likelihood of a recurrent hypersensitivity reaction when a comprehensive allergologic evaluation cannot be performed in time.
Group 1 agents sharing similar carbamoyl side chains, particularly iohexol, iodixanol, iomeprol and ioversol, showed the highest rates of cross-reactivity across the available studies on positive skin tests.
Iopromide behaved much like these Group 1 agents despite belonging to a different structural class. Iopamidol and iobitridol could act as potentially attractive alternative agents when formal allergy testing isn't available, whereby iobitridol demonstrated low cross-reactivity. Unfortunately, iopamidol is no longer available in many European markets, van der Molen noted.
If possible, allergologic evaluation remains the optimal choice
The authors stress that the framework is intended to support, not replace, a comprehensive allergologic evaluation, which remains the gold standard for elective examinations.
However, for emergency imaging, hospitalized patients, follow-up in oncology trials and for healthcare settings with limited allergy services, van der Molen believes it can provide radiologists with a more evidence-based approach than just trial and error.
"The literature is not perfect, and the evidence is of low quality," he cautioned, noting that most available studies are observational and rely largely on skin-test results rather than large prospective randomized trials.
Nevertheless, the goal is to give radiologists working in areas with limited allergology capacity "some extra background to help Choosing Wisely." But, he emphasized, "it is not a perfect tool."
Accurate documentation of the hypersensitivity is essential
As the guidelines shift from routine premedication regardless of the culprit ICM to changing the specific ICM and allergologic testing, an accurate and detailed documentation of the hypersensitivity reaction is now more important than ever, the author stresses.
Such documentation in the allergy module of the electronic medical record should include the name and dose of the specific ICM agent that caused the reaction, the symptoms, the therapy given, the outcome of the patient, and recommendations for future imaging, he suggested.
